MedTrace Logo

The Effects of Hemodialysis on Serum Sclerostin Levels

NCT03952819 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 56

Last updated 2019-05-16

No results posted yet for this study

Summary

Background: Parathyroid hormone (PTH) and 1,25-dihydroxy vitamin D (1,25-OHD) as well as mineral bone metabolism modulators like sclerostin are thought to play an important role in in diabetic patients with chronic renal failure. The present study aimed to analyse the levels of serum sclerostin before and after hemodialysis which is a primary element of treatment in such combined disease states.

Methods: Serum sclerostin concentrations were measured using a commercially available enzyme-linked immunosorbent assay kit with 56 individuals who 14 chronic hemodialysis patients with diabetes, 14 chronic hemodialysis patients with non-diabetes and 28 healthy volunteers as a control group.

Conditions

Interventions

DIAGNOSTIC_TEST

serum sclerostin

blood samples obtained

Sponsors & Collaborators

  • Abant Izzet Baysal University

    lead OTHER

Principal Investigators

  • Ozgur M. Yis · BAİBÜ

Eligibility

Min Age
44 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-09-14
Primary Completion
2018-11-15
Completion
2018-12-15

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03952819 on ClinicalTrials.gov